Quick overview of what we’ll cover in this blog post:
- Current progress on Long COVID
- How LDN & NAD+ shows promise
- The results of our Long COVID study
- What this means for the future of Long COVID
Long COVID currently lacks any effective treatment strategies, let alone any approved by the FDA, leaving close to 18 million Americans struggling with debilitating brain fog and chronic fatigue, among other symptoms.
Meanwhile, researchers are racing to test any therapy or drug combination that may offer relief, with limited success: since Long COVID symptoms first emerged, only a small handful of viable treatment options have been identified, and even those don’t typically have great long-term efficacy.
After noticing that a combination of Low Dose Naltrexone and NAD+ treatment reduced fatigue and boosted energy in patients, our experts at AgelessRx launched a study to see how these treatments could help those struggling with Long COVID symptoms.
What Did the Study Show?
After 12 weeks of testing and nearly three years of preparation, our study found that 52% of participants showed substantial improvements to their energy, pain, and physical health when using both Low Dose Naltrexone and NAD+ treatments. This resulted in a 20% improvement in quality of life, including a significant reduction in fatigue symptoms, even in patients who had tried other interventions.
During the study, patients aged between 18 and 65 were asked to fill out clinically validated, self-reported surveys to assess their fatigue levels and overall quality of life while taking Low Dose Naltrexone and NAD+ iontophoresis patches. Among the surveys used were the Chalders Fatigue Scale, one of the most robust clinical scales for evaluating fatigue, and the SF-36, which is considered by many as the standard for evaluating quality of life.
The surveys measured eight different markers of our quality of life: physical health, emotional wellness, social function, pain, physical limitations, emotional limitations, energy and fatigue, and overall health.
This means that more than half of the participants showed improvement across all eight measures of our quality of life. A 20% increase in quality of life is exceptional, especially for Long COVID studies, suggesting that Low Dose Naltrexone and NAD+ address more than one symptom of Long COVID.
What Does This Mean for Long COVID?
These findings indicate that a combination of Low Dose Naltrexone and NAD+ therapy could not only reduce fatigue in Long COVID patients, but improve their overall quality of life.
Though more research is needed before these are confirmed as viable treatment options, the results suggest that we may be on the cusp of confirming a holistic treatment for Long COVID symptoms that address the underlying pathology of the condition.
This unlocks a new path for scientists to explore as we navigate the post-pandemic world, moving us closer to an FDA-approved treatment for Long COVID.
Interested in learning more about our study? You can read the full study for free at Science Direct.
Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.